Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action filed by Robbins Geller Rudman & Dowd LLP

Core Viewpoint - The Soleno complaint alleges that the Phase 3 clinical trial program for DCCR has downplayed, misrepresented, and/or concealed safety concerns [1] Group 1 - The complaint specifically targets the safety concerns related to the DCCR clinical trial [1]